Capstone Investment Advisors
PACB icon

Capstone Investment Advisors’s Pacific Biosciences PACB Stock Holding History

Capstone Investment Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-61,790
Closed -$232K – 2360
2024
Q1 		$232K Buy
61,790
+42,949
+228% +$251K ﹤0.01% 1953
2023
Q4 		$185K Buy
+18,841
New +$154K ﹤0.01% 1807
2022
Q2 		– Sell
-10,498
Closed -$96K – 2035
2022
Q1 		$96K Buy
+10,498
New +$121K ﹤0.01% 1858
2020
Q1 		– Sell
-205,337
Closed -$1.05M – 1328
2019
Q4 		$1.05M Sell
205,337
-15,108
-7% -$76.8K 0.01% 989
2019
Q3 		$1.14M Sell
220,445
-231,785
-51% -$1.3M 0.01% 897
2019
Q2 		$2.74M Buy
452,230
+204,917
+83% +$1.44M 0.02% 653
2019
Q1 		$1.79M Sell
247,313
-370,579
-60% -$2.68M 0.02% 648
2018
Q4 		$4.57M Buy
+617,892
New +$3.91M 0.06% 259
2016
Q3 		– Sell
-18,500
Closed -$130K – 876
2016
Q2 		$130K Buy
+18,500
New +$169K ﹤0.01% 642

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's PACB Position: Q2 2024 in Review

Capstone Investment Advisors sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 61,790 shares — an estimated $232K sold.

Capstone Investment Advisors first reported a position in PACB in Q2 2016 and held it in 9 quarters. The position peaked at $4.57M in Q4 2018. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Capstone Investment Advisors reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 61,790 Pacific Biosciences shares in Q2 2024, an estimated $232K.
  • Capstone Investment Advisors first reported a position in Pacific Biosciences in Q2 2016 and held it in 9 quarters.
  • Capstone Investment Advisors's Pacific Biosciences position peaked at $4.57M in Q4 2018.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.